{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T10:54:48Z","timestamp":1764240888444,"version":"build-2065373602"},"reference-count":25,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T00:00:00Z","timestamp":1756598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Hepatocellular carcinoma (HCC) is the most common primary liver cancer. At the time of diagnosis, many HCC patients are not candidates for surgical resection and are considered for other locoregional therapies, including transarterial radioembolization (TARE) and stereotactic body radiation therapy (SBRT). To date only a few studies have explored the safety and efficacy of combining TARE and SBRT. Therefore, we aimed to evaluate it. Patients who received both SBRT and TARE from 2016 to 2024 were retrospectively evaluated for treatment-related toxicity based on criteria for adverse events (CTCAE v4.0). Treatment response was evaluated by modified response evaluation criteria for solid tumors (m-RECIST). We identified 12 patients with median age of 66.5 (range: 40, 87) and median follow up of 12 months. The median time between TARE and SBRT was 6.5 months (range: 1.5 to 24). Following the second treatment, ALBI grade remined the same among all patients at 3-month post treatment compared to baseline. Baseline CP was A among all patients and remained unchanged during follow-up and no higher than grade 3 clinical or biochemical toxicity was seen. The objective response rate (ORR) among patients receiving treatment to the same lesion was 100%. The combination treatment was consistent with prior studies in which the combination of TARE and SBRT has been shown to have good local control with few cases of grade 3 toxicity. Our study demonstrates that treatment with TARE and SBRT was safe and effective among our small sample of patients.<\/jats:p>","DOI":"10.3390\/curroncol32090487","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T09:24:41Z","timestamp":1756805081000},"page":"487","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety of Combination TARE and SBRT in Hepatocellular Carcinoma: A Review of Literature &amp; Single-Center Case Series"],"prefix":"10.3390","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3260-4904","authenticated-orcid":false,"given":"Bahareh","family":"Gholami","sequence":"first","affiliation":[{"name":"Division of Vascular and Interventional Radiology, Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Afrasiabi","sequence":"additional","affiliation":[{"name":"Division of Vascular and Interventional Radiology, Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew M.","family":"Moon","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7123-0637","authenticated-orcid":false,"given":"Ted K.","family":"Yanagihara","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2346-8621","authenticated-orcid":false,"given":"Hui","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Vascular and Interventional Radiology, Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5872-2686","authenticated-orcid":false,"given":"Sandra","family":"Gad","sequence":"additional","affiliation":[{"name":"Division of Vascular and Interventional Radiology, Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Villalobos","sequence":"additional","affiliation":[{"name":"Division of Vascular and Interventional Radiology, Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Mauro","sequence":"additional","affiliation":[{"name":"Division of Vascular and Interventional Radiology, Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4318-2575","authenticated-orcid":false,"given":"Hyeon","family":"Yu","sequence":"additional","affiliation":[{"name":"Division of Vascular and Interventional Radiology, Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes L.","family":"du Pisanie","sequence":"additional","affiliation":[{"name":"Division of Vascular and Interventional Radiology, Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nima","family":"Kokabi","sequence":"additional","affiliation":[{"name":"Division of Vascular and Interventional Radiology, Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,31]]},"reference":[{"key":"ref_1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejca.2021.11.023","article-title":"Global, regional and national burden of primary liver cancer by subtype","volume":"161","author":"Rumgay","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.3748\/wjg.14.3452","article-title":"Selection criteria for liver resection in patients with hepatocellular carcinoma and chronic liver disease","volume":"14","author":"Delis","year":"2008","journal-title":"World J. Gastroenterol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13014-017-0851-7","article-title":"Excellent local control and tolerance profile after stereotactic body radiotherapy of advanced hepatocellular carcinoma","volume":"12","author":"Gkika","year":"2017","journal-title":"Radiat. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s12029-017-9990-1","article-title":"SBRT for Hepatocellular Carcinoma: 8-Year Experience from a Regional Transplant Center","volume":"49","author":"Qiu","year":"2018","journal-title":"J. Gastrointest. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.semradonc.2017.02.002","article-title":"Advances in Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma","volume":"27","author":"Murray","year":"2017","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.radonc.2014.05.002","article-title":"Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma","volume":"111","author":"Culleton","year":"2014","journal-title":"Radiother. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ijrobp.2023.08.015","article-title":"Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Meta-Analysis and International Stereotactic Radiosurgery Society Practice Guidelines","volume":"118","author":"Bae","year":"2024","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S2468-1253(22)00091-7","article-title":"Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): A single-centre, single-arm study","volume":"7","author":"Kim","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1016\/j.ijrobp.2021.07.354","article-title":"Stereotactic body radiotherapy and yttrium-90 in the treatment of hepatocellular carcinoma: A comparison of outcomes and costs","volume":"111","author":"Harris","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.brachy.2021.01.006","article-title":"ACR\u2013ABS\u2013ACNM\u2013ASTRO\u2013SIR\u2013SNMMI practice parameter for selective internal radiation therapy or radioembolization for treatment of liver malignancies","volume":"20","author":"Hong","year":"2021","journal-title":"Brachytherapy"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ijrobp.2013.05.041","article-title":"Safety of 90Y radioembolization in patients who have undergone previous external beam radiation therapy","volume":"87","author":"Lam","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.ijrobp.2019.09.006","article-title":"Safety and Efficacy of Liver Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma After Segmental Transarterial Radioembolization","volume":"105","author":"Lazarev","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3857\/roj.2021.00213","article-title":"Combination of yttrium-90 radioembolization with stereotactic body radiation therapy in the treatment of portal vein tumor thrombosis","volume":"39","author":"Liu","year":"2021","journal-title":"Radiat. Oncol. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1118\/1.3608909","article-title":"Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for 90Y microsphere brachytherapy in the treatment of hepatic malignancies","volume":"38","author":"Dezarn","year":"2011","journal-title":"Med. Phys."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ijrobp.2017.12.290","article-title":"Radiation Dose-Volume Effects for Liver SBRT","volume":"110","author":"Miften","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1016\/j.ijrobp.2009.06.092","article-title":"Radiation-associated liver injury","volume":"76","author":"Pan","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_19","first-page":"35","article-title":"Oncologic outcomes and rates of hepatotoxicity following stereotactic body radiotherapy for hepatocellular carcinoma","volume":"10","author":"Whitmill","year":"2024","journal-title":"Hepatoma Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1097\/01.RVI.0000233785.75257.9A","article-title":"Radioembolization with 90Yttrium microspheres: A state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations","volume":"17","author":"Salem","year":"2006","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.cpet.2025.03.002","article-title":"Post-Y90 PET Dosimetry","volume":"20","author":"Afrasiabi","year":"2025","journal-title":"PET Clin."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00270-007-9064-z","article-title":"Radioembolization with 90Y microspheres: Angiographic and technical considerations","volume":"30","author":"Lewandowski","year":"2007","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jhep.2019.09.026","article-title":"mRECIST for HCC: Performance and novel refinements","volume":"72","author":"Llovet","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.suronc.2019.01.006","article-title":"Better survival after stereotactic body radiation therapy following transarterial chemoembolization in nonresectable hepatocellular carcinoma: A propensity score matched analysis","volume":"28","author":"Wong","year":"2019","journal-title":"Surg. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jamaoncol.2017.5847","article-title":"Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial","volume":"4","author":"Yoon","year":"2018","journal-title":"JAMA Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/9\/487\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:36:27Z","timestamp":1760034987000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/9\/487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,31]]},"references-count":25,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["curroncol32090487"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32090487","relation":{},"ISSN":["1718-7729"],"issn-type":[{"type":"electronic","value":"1718-7729"}],"subject":[],"published":{"date-parts":[[2025,8,31]]}}}